Developmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukaemia
MetadataShow full item record
This item's downloads: 0 (view details)
Cited 1 times in Scopus (view citations)
Giles, Francis; Mahon, François-Xavier; Gjertsen, Bjorn; Swords, Ronan; Labar, Boris; Turkina, Anna; Rosti, Gianantonio (2012). Developmental therapeutics consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation 42 (9), 1016-1026
Eur J Clin Invest 2012; 42 (9): 10161026 Abstract Background Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukaemia (CML). Results from ongoing phase 3 trials with nilotinib [Efficacy and Safety in Clinical TrialsNewly Diagnosed Patients (ENESTnd)] and dasatinib [Dasatinib Versus Imatinib Study in Treatment-Naive CML-CP Patients (DASISION)] in newly diagnosed patients with CML in chronic phase have demonstrated that these TKIs resulted in significant improvements in responses vs. imatinib. Design The Developmental Therapeutics Consortium (DTC) systematically reviewed the published literature to provide a comparative analysis of the ENESTnd and DASISION trial designs and data reported on each study. Results The recent approval of nilotinib and dasatinib based on these two pivotal studies offers physicians the option to optimise frontline treatment based on a patients comorbidities, risk factors and tolerability profiles. Although nilotinib and dasatinib provide effective therapeutic options for the frontline treatment of CML, the lack of an evidenced-based, side-by-side comparison makes it difficult to directly compare these agents. Conclusions Despite potential bias from differences in patient populations and study design, indirect cross-trial comparisons to determine the relative effectiveness of these agents will be performed by physicians. This DTC report provides a comprehensive summary of the study designs, protocols and results of the ENESTnd and DASISION trials, which will assist physicians in making informed decisions on the best treatment approach for their patients.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Showing items related by title, author, creator and subject.
Mahnken, Andreas H.; Thomson, Ken; de Haan, Michiel; O’Sullivan, Gerard J. (Springer Nature, 2014-03-15)Chronic venous insufficiency (CVI) as an advanced stage of chronic venous disease is a common problem that occurs in approximately 1-5 % of the adult population. CVI has either a nonthrombotic (primary) or postthrombotic ...
Kim, T. D.; le Coutre, P.; Schwarz, M.; Grille, P.; Levitin, M.; Fateh-Moghadam, S.; Giles, F. J.; Dorken, B.; Haverkamp, W.; Kohncke, C. (Ferrata Storti Foundation (Haematologica), 2012-01-22)Background Nilotinib is a second-generation tyrosine kinase inhibitor with significant efficacy as first-or second-line treatment in patients with chronic myeloid leukemia. Despite preclinical evidence indicating a risk ...
Reddan, D. N.; Szczech, L.; Bhapkar, M. V.; Moliterno, D. J.; Califf, R. M.; Ohman, E. M.; Berger, P. B.; Hochman, J. S.; Van de Werf, F.; Harrington, R. A.; Newby, L. K.; , (Oxford University Press (OUP), 2005-07-19)Background. Chronic kidney disease (CKD) is highly prevalent in patients with cardiovascular disease. We explored the associations of CKD with outcomes using combined data from two large acute coronary syndrome (ACS) trials. ...